Abstract

Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date

Author(s): Peacock Gina F, Sauvageot Jurgita, Hill Ashley, Killian Alyssa

Issue: Jan/Feb 2016 - Volume 20, Number 1

Page(s): 81-85

Download in electronic PDF format for $75
  • Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date Page 1
  • Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date Page 2
  • Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date Page 3
  • Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date Page 4
  • Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date Page 5

Abstract

Mercaptopurine is commonly used to treat acute lymphoblastic leukemia and has historically been commercially available only in tablet form. Since tablets may be difficult for children and elderly patients to swallow, many pharmacists have compounded mercaptopurine suspensions. The U.S. Food and Drug Administration recently approved a commercial suspension, but it is not widely available at this time. Therefore, pharmacists may still need to compound mercaptopurine suspension for use in areas where it is not available or if the commercial suspension is in short supply. Stability studies must be conducted in order to assign appropriate beyond-use dates for compounded preparations. The objective of this study was to evaluate the stability of extemporaneously compounded suspensions using commercially available mercaptopurine tablets, as well as active pharmaceutical ingredient in a vehicle of Ora-Sweet and Ora- Plus (1:1) stored in plastic and glass containers at room temperature. Each mercaptopurine preparation was analyzed using a validated stability-indicating high-performance liquid chromatography method at the following time points: 0, 7, 14, 21, 30, 60, and 90 days. Suspensions were also observed for changes in appearance or odor, and pH was tested at each time point. The suspension compounded from Roxane generic tablets was extremely viscous and was therefore eliminated from the study. All other suspensions showed no observed physical changes and maintained greater than 93% of initial concentration of mercaptopurine for the entire study period.

Related Keywords

  • mercaptopurine
  • acute lymphoblastic leukemia
  • oral suspension
  • stability
  • chemotherapy
  • formulations
  • beyond-use date
  • packaging
  • storage

Related Categories

  • CANCER AND AIDS
  • EXCIPIENTS
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • STORAGE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2016
Pg. 81-85
Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date
Author(s): Peacock Gina F, Sauvageot Jurgita, Hill Ashley, Killian Alyssa
Jan/Feb 2021
Pg. 73-81
Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design
Author(s): Patel Gopesh, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S
Jul/Aug 2014
Pg. 345-347
Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Author(s): Peacock Gina F, Sauvageot Jurgita
Jul/Aug 2014
Pg. 348-350
Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Author(s): Peacock Gina F, Sauvageot Jurgita, Addo Richard T
May/Jun 2014
Pg. 253-255
Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Author(s): Peacock Gina F, Sauvageot Jurgita
Nov/Dec 2014
Pg. 456-460
Standards of Practice, Professional Judgment, and Scientific Evidence to Establish and Extend a Beyond-Use Date
Author(s): Thomson Cassandra Marie, Savji Taslim
Nov/Dec 2012
Pg. 471-474
Beyond-use Date: Establishment and Maintenance
Author(s): Osteen Richard
Mar/Apr 2017
Pg. 164-170
Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs
Author(s): Gorman Gregory, Sokom Simara, Coward Lori, Arnold John J
Jul/Aug 2018
Pg. 303-312
Basics of Sterile Compounding: Criteria for Determining Beyond-use Dating
Author(s): Martin Matt
Jan/Feb 2018
Pg. 51
Mercaptopurine 50 mg/mL in Ora-Sweet and Ora-Plus Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2014
Pg. 169-174
Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets
Author(s): Zaid Abdel Naser, Assali Mohyeddin, Qaddomi Aiman, Ghanem Mashhour, Zaaror Yara Abu
Sep/Oct 2012
Pg. 428-430
Evaluation of the Stability of Acetaminophen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-Use Date
Author(s): Peacock Gina F, Sauvageot Jurgita
Nov/Dec 2008
Pg. 524-528
Quality-Control Analytical Methods: Overview of Beyond-Use Dating for Compounded Sterile Preparations
Author(s): Trissel Lawrence A
Jul/Aug 2008
Pg. 344-353
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 8; Stability and Beyond-Use Dating
Author(s): Allen Loyd V Jr, Okeke Claudia C
May/Jun 2010
Pg. 232-238
Basics of Compounding: Considerations for Implementing USP Chapter <797> -- Sterile Preparations, Part 19: Storage and Beyond-Use Dating, Maintaining Sterility, Purity, and Stability of Dispensed and Distributed Compounded Sterile Preparations
Author(s): Okeke Claudia C, Allen Loyd V Jr
Nov/Dec 2010
Pg. 522-525
Stability of Methimazole in Poloxamer Lecithin Organogel to Determine Beyond-Use Date
Author(s): Pignato Alyssa, Pankaskie Marvin, Birnie Christine
Mar/Apr 2021
Pg. 169-175
Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt
Author(s): Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Le Giang, Morris Tommy C, Graves Richard A
Jan/Feb 2001
Pg. 9-12
Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Author(s): Schotik Debora
Sep/Oct 2003
Pg. 389-393
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Author(s): Alexander Kenneth S, Thyangarajapuram N
Nov/Dec 2018
Pg. 516-526
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira